Wave Life Sciences (WVE) Free Cash Flow (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Free Cash Flow came in at -$54.5 million in Q2 2026, down 17.59% YoY from -$66.1 million in Q2 2025, and up 9.21% on a QoQ basis from -$60.0 million in Q1 2026.
Wave Life Sciences (WVE) Free Cash Flow (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Free Cash Flow data on file, last reported at -$54.5 million in Q2 2026.
- Quarterly Free Cash Flow fell 17.59% year-over-year to -$54.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$193.1 million (up 3.48% YoY) and the FY2025 annual result came in at -$188.2 million, down 23.85% from the prior year.
- Free Cash Flow rose to -$54.5 million in Q2 2026, from -$60.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $85.0 million in Q1 2023 to a low of -$63.2 million in Q1 2025.
- A 5-year average of -$33.6 million and a median of -$36.0 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 377.36% — and 2023, when it surged 312.15%.
- Tracing WVE's Free Cash Flow over 5 years: stood at -$33.6 million in 2022, then advanced by 0.15% to -$33.6 million in 2023, then tumbled by 30.18% to -$43.7 million in 2024, then rose by 22.77% to -$33.8 million in 2025, then sank by 61.26% to -$54.5 million in 2026.
- The last three Free Cash Flow figures came in at -$54.5 million (Q2 2026), -$60.0 million (Q1 2026), and -$33.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | -54.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.47 Mn |
| Jun 30, 2026 | -54.47 Mn |
| Mar 31, 2026 | -59.99 Mn |
| Mar 31, 2026 | -59.99 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Sep 30, 2025 | -44.91 Mn |
| Sep 30, 2025 | -44.91 Mn |
| Jun 30, 2025 | -46.32 Mn |
| Jun 30, 2025 | -46.32 Mn |
| Mar 31, 2025 | -63.20 Mn |
| Mar 31, 2025 | -63.20 Mn |
| Dec 31, 2024 | -43.73 Mn |
| Dec 31, 2024 | -43.73 Mn |
| Sep 30, 2024 | -46.86 Mn |
| Sep 30, 2024 | -46.86 Mn |
| Jun 30, 2024 | -27.52 Mn |
| Jun 30, 2024 | -27.52 Mn |
| Mar 31, 2024 | -33.85 Mn |
| Mar 31, 2024 | -33.85 Mn |